KeyBank National Association
NVCR icon

KeyBank National Association’s NovoCure NVCR Stock Holding History

KeyBank National Association’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-1,977
Closed -$261K – 1079
2021
Q1 		$261K Sell
1,977
-917
-32% -$145K ﹤0.01% 963
2020
Q4 		$501K Hold
2,894
– – ﹤0.01% 763
2020
Q3 		$322K Buy
+2,894
New +$231K ﹤0.01% 821

Other funds holding NVCR

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

KeyBank National Association's NVCR Position: Q2 2021 in Review

KeyBank National Association sold out of NovoCure (NVCR) in Q2 2021, closing a stake of 1,977 shares — an estimated $261K sold.

KeyBank National Association first reported a position in NVCR in Q3 2020 and held it in 3 quarters. The position peaked at $501K in Q4 2020. 361 funds tracked by Wall St. Rank hold NVCR as of Q2 2021.

  • KeyBank National Association reported no remaining NovoCure position as of Q2 2021 after selling out during the quarter.
  • KeyBank National Association sold 1,977 NovoCure shares in Q2 2021, an estimated $261K.
  • KeyBank National Association first reported a position in NovoCure in Q3 2020 and held it in 3 quarters.
  • KeyBank National Association's NovoCure position peaked at $501K in Q4 2020.
  • 361 funds tracked by Wall St. Rank held NovoCure as of Q2 2021.

Based on KeyBank National Association's 13F filing for Q2 2021, filed 12 Aug 2021.